Tarsus Pharmaceuticals (TARS) FY Conference Summary Company Overview - Tarsus Pharmaceuticals is a commercial stage biotech company focused on the eye care space, specifically targeting Demodex Blepharitis with its drug Xtampi, launched in September 2023 [4][5]. Industry Insights - The eye care market is significant, with approximately 25 million patients in the U.S. affected by Demodex Blepharitis, and Tarsus is targeting 9 million patients actively seeking treatment [5]. Key Launch Insights - The launch of Xtampi has been successful, with sequential increases in demand and revenue [5]. - Commercial coverage was achieved earlier than expected, with Medicare coverage starting in early 2025 [6]. Sales Force Expansion - Tarsus expanded its sales force by hiring 50 additional sales representatives, which has positively impacted the frequency of doctor visits and prescription rates [6][7]. - It takes an average of 5 to 10 visits for sales reps to convert doctors to regularly prescribe Xtampi [8][9]. Prescribing Patterns - Tarsus targets about 15,000 eye care professionals (ECPs) who write 85% of scripts in the dry eye space [10]. - As of December, 40% of ECPs were prescribing Xtampi beyond the Demodex Blepharitis category [11]. - The company has dispensed approximately 225,000 scripts, indicating significant room for growth given the target of 9 million patients [15]. Future Growth and Guidance - Tarsus expects to see continued growth in bottle dispensed, although percentage growth may slow as the base grows larger [22]. - The company anticipates a guidance of 85,000 to 90,000 new prescriptions for the second quarter, factoring in seasonal impacts [20]. Refill Dynamics - Currently, 8-9% of prescriptions are refills, with a target of reaching a 20% refill rate based on clinical history [24][25]. - The company is focused on acquiring new patients as the primary growth driver, rather than relying heavily on refills [26]. Direct-to-Consumer (DTC) Campaign - Tarsus has budgeted $70 million to $80 million for DTC advertising, including streaming and network TV campaigns [42]. - The DTC campaign aims to increase patient engagement and script dispensation, with expected impacts to be seen in the latter half of the year [44][46]. International Development Plans - Tarsus has partnered with Grand Pharma for its drug approval in China, which typically takes 18-24 months [49][50]. - European approval is anticipated in the second half of 2027, contingent on regulatory requirements for a preservative-free formulation [51][52]. Pipeline Developments - Tarsus is preparing to initiate a Phase 2 study for ocular rosacea, targeting a significant unmet need in the market [58][60]. - The company is also exploring a potential Lyme disease treatment, with plans for a Phase 2b study in 2026 [70][73]. Intellectual Property Strategy - Tarsus holds strong intellectual property protections, with patents extending through 2038 and beyond for various uses of its products [75][76]. Conclusion - Tarsus Pharmaceuticals is positioned for growth in the eye care market with a successful product launch, an expanding sales force, and a robust pipeline of future treatments. The company is actively engaging in DTC marketing and exploring international opportunities while maintaining a strong focus on intellectual property.

Summary of Tarsus Pharmaceuticals Conference Call Company Overview - Tarsus Pharmaceuticals is a commercial stage company focused on the eye care space, having launched its product Xtembi in August 2023 [2][3] - Xtembi is an eye drop treatment for demodex blepharitis, showing significant efficacy with 85% of patients experiencing clinically meaningful improvement [4][3] Market Opportunity - Demodex blepharitis affects approximately 25 million Americans, with a specific target market of about 9 million patients currently in clinics [10][12] - The company has only treated a couple hundred thousand patients since launch, indicating substantial growth potential [12] Product Efficacy and Safety - Xtembi is easy to diagnose and has a simple treatment paradigm, contributing to its success [5][4] - The treatment is a six-week course, administered twice daily [33] Pipeline Developments - Tarsus plans to initiate a Phase II study for ocular rosacea, a condition affecting 15-18 million patients, with a significant unmet need [6][58] - The company is also exploring the use of the same active ingredient in Xtembi for Lyme disease, with promising Phase II data showing a 97% tick kill rate within 24 hours [7][64] Sales and Marketing Strategy - Tarsus has one of the largest eye care sales forces, with 150 representatives targeting both ophthalmologists and optometrists [44][45] - The company is focusing on physician education to increase awareness of demodex blepharitis and the importance of diagnosing it during eye exams [15][16] Financial Performance - Tarsus reported $78 million in revenue for Q1, with guidance for Q2 indicating 85,000 to 90,000 bottles dispensed [25][26] - The gross to net discount was approximately 47% in Q1, expected to decrease to 42-43% by Q4 [25][27] Direct-to-Consumer (DTC) Campaign - The company plans to spend $70-80 million on DTC marketing, focusing on various media channels [38] - The effectiveness of the DTC campaign will be closely monitored to ensure a positive return on investment [39][41] Future Guidance - Tarsus is not providing annual revenue guidance yet but is optimistic about continued growth driven by its sales force and DTC efforts [50][51] - The company anticipates a 20% annualized retreatment rate for patients, indicating potential for recurring revenue [30][32] International Expansion - Tarsus is exploring opportunities in Europe and Japan, with potential NDA filings expected by 2027 [53][54] - The company is assessing pricing dynamics and regulatory requirements in these markets [54][55] Cash Position - As of Q1, Tarsus had approximately $48 million in cash, providing a healthy balance sheet to support ongoing operations and clinical studies [68]

Summary of Tarsus Pharmaceuticals (TARS) FY Conference Call Company Overview - Tarsus Pharmaceuticals is a commercial stage company focused on eye care, with its first medicine, Xtendvi, launched in September 2023, showing potential blockbuster status with projected revenues over a billion dollars [4][15][74]. Key Products and Pipeline - **Xtendvi**: Launched successfully with quarter-over-quarter growth and strong underlying demand. The product targets Demodex blepharitis, a prevalent condition affecting approximately 25 million patients in the U.S. [4][9][10]. - **Ocular Rosacea Treatment**: A new product in development using the same active ingredient as Xtendvi, aimed at a market with no FDA-approved therapeutics [5][58]. - **Lyme Disease Treatment**: An oral prophylactic treatment that Tarsus plans to outlicense, with a phase two study anticipated next year [6][68]. Market Dynamics and Growth Factors - The company has targeted 15,000 eye care professionals, achieving 90% coverage across all payers, which has facilitated the growth of Xtendvi [12][10]. - The sales force has expanded, with a focus on educating eye care professionals and patients about Demodex blepharitis, leading to increased prescriptions [18][19][20]. - Direct-to-consumer (DTC) campaigns initiated in Q4 2023 have driven consumer awareness and demand, although the impact on prescription volume is expected to materialize over one to two quarters [39][44]. Financial Performance and Projections - Initial revenue projections for 2024 were around $55 million, which the company has tripled due to strong market adoption and effective sales strategies [15][17]. - Gross-to-net discounts are expected to decline to a target range of 42-43% by the end of the year, influenced by the introduction of Medicare Part D coverage [54][56]. Clinical Data and Efficacy - Clinical data for Xtendvi showed that 85% of patients experienced clinically meaningful improvement with a benign safety profile [9]. - The company is focused on demonstrating the efficacy of its products through ongoing studies and market research, particularly for ocular rosacea and Lyme disease [60][71]. Challenges and Considerations - The company faces challenges in educating physicians about the prevalence of Demodex blepharitis and the need for treatment, as many patients may be asymptomatic [22][26]. - The need for a reproducible scale for clinical endpoints in the ocular rosacea study is critical for regulatory approval [63][65]. Cash Position - As of Q1 2025, Tarsus reported a cash balance of approximately $408 million, with future guidance on cash flow positive status pending revenue evaluations [74]. Conclusion - Tarsus Pharmaceuticals is positioned for growth with a strong product pipeline and effective market strategies, but it must continue to navigate educational challenges and regulatory requirements to maximize its potential in the eye care market.

Tarsus Pharmaceuticals (TARS) 2025 Conference May 27, 2025 10:30 AM ET Speaker0 Great. Good morning, everyone, and thanks for joining us for the TARSIS, fireside chat. It's our pleasure to have Jeff Farrow with us, CFO and chief strategy officer, of Tarsus. And to kick it off, you know, you know, to start start with, you've had a very successful development of Xtampi, which and now commercial execution. Maybe just to get everyone on the same page, can you just start with an overview, make sure everybody kno ...

Tarsus Pharmaceuticals (TARS) FY 2025 Conference May 20, 2025 03:00 PM ET Speaker0 All right. So I guess we'll get started here. Welcome, everyone. My name is Matthew Caulfield. I'm a senior biotech analyst here at H. C. Wainwright. Our next speaker or next guest will be Tarsus Pharmaceuticals, and we're joined by Jeff Farrow, CFO and Chief Strategy Officer. So Jeff, thank you so much for joining us. Thank you for having us. Welcome to Tarsus. So to start off, maybe we could discuss the approved product, Xt ...

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) has experienced significant selling pressure, resulting in a 15.6% decline in stock price over the past four weeks, but analysts anticipate improved earnings reports in the near future [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - TARS has an RSI reading of 29.83, suggesting that the heavy selling may be exhausting, potentially leading to a price rebound [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for TARS by 19.5% over the last 30 days, indicating a positive trend that typically correlates with price appreciation [6] - TARS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround [7]

Summary of Tarsus Pharmaceuticals (TARS) 2025 Conference Call Company Overview - Tarsus Pharmaceuticals is a commercial company based in Orange County, California, focusing on eye care treatments, particularly the launch of their drug Xtampi for blepharitis treatment [3][4]. Key Highlights - **Product Launch Success**: The launch of Xtampi has exceeded expectations, with Q1 revenue recorded at approximately $78.2 million, representing a 20% growth from Q4 [4]. - **Market Potential**: The drug targets a significant patient population, with an estimated 25 million patients in the U.S. suffering from demodex-related conditions, and aims to reach 9 million patients actively visiting doctors [3][4]. - **Sales Force Impact**: The expansion of the sales force has been a major tailwind, contributing to extraordinary growth in Q1, surpassing initial expectations despite typical seasonal challenges [19][20]. Financial Metrics - **Revenue and Dispensed Bottles**: In Q1, Tarsus dispensed 72,000 bottles of Xtampi, with a gross-to-net discount of about 47%, expected to decline to the low 40s in subsequent quarters [4]. - **Patient Coverage**: Over 90% of lives are covered by payers for Xtampi, which is considered remarkable in the current environment [11][12]. Pipeline Developments - **Ocular Rosacea**: Tarsus is initiating a Phase II study for ocular rosacea, targeting 15-18 million patients, with no current FDA-approved treatments available [5][58]. - **Lyme Disease Program**: A prophylactic oral treatment for Lyme disease is also in the pipeline, with plans for a Phase 2b study in 2026 [6]. Competitive Landscape - **Lack of Competition**: Xtampi is positioned as a best-in-class product with no direct competition, as existing treatments do not effectively address the root cause of demodex infestation [10][16]. - **Potential Complementary Products**: Other products in development, such as pimecrilimus, may serve as complementary treatments rather than direct competitors [14][15]. Market Dynamics - **Optometrist Engagement**: The trend of optometrists taking on more medical management roles is increasing, allowing them to bill for comprehensive exams and follow-ups, which enhances patient retention and practice growth [34][37]. - **Direct-to-Consumer (DTC) Marketing**: The DTC program is showing promising early results, with increased website visits and engagement correlating with future prescription growth [29][30]. Future Outlook - **TAM Growth**: The total addressable market (TAM) is expected to grow, with the potential to treat a significant portion of the 9 million targeted patients over time [45][46]. - **Data Generation**: Tarsus plans to conduct multiple Phase IV studies to expand its market presence and validate the efficacy of its products across various patient segments [48]. Regulatory and Market Considerations - **Medicare Part D Impact**: The introduction of Medicare Part D coverage has reduced friction for patient access, positively impacting revenue [50][52]. - **Exploration of International Markets**: Tarsus is considering opportunities in Europe but currently focuses on the U.S. market [56]. Conclusion - Tarsus Pharmaceuticals is positioned for significant growth with its innovative product offerings and strategic market engagement, particularly in the eye care sector. The company is optimistic about its future prospects, driven by a strong sales force, effective marketing strategies, and a robust pipeline of new treatments.

Core Insights - Tarsus Pharmaceuticals has launched a direct-to-consumer TV campaign for its eyedrop Xdemvy (lotilaner) aimed at treating Demodex blepharitis, marking a significant marketing strategy just over a year after the product's launch [1] Company Summary - Tarsus Pharmaceuticals is actively promoting its product Xdemvy through a direct-to-consumer approach, indicating a shift towards more aggressive marketing tactics to enhance product visibility and sales [1]

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.25%. A quarter ago, it was expected that this company would post a loss of $0.68 per share when it actually produced a loss of $0.60, delivering a surprise of 11.76%.Over the last four quarters, the company ...

Tarsus Pharmaceuticals (TARS) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants David Nakasone - Head of Investor Relations (IR)Bobak Azamian - Co-Founder, President, CEO & ChairmanAziz Mottiwala - Chief Commercial OfficerJeff Farrow - CFO and CSOSesha Neervannan - COOAndrea Newkirk - Biotechnolgy Equity ResearchEddie Hickman - Vice President Conference Call Participants Lachlan Hanbury-Brown - Biotech Equity Research AnalystPavan Patel - AnalystCory Jubinville - Managing Director & Resear ...